Updated agenda for the July 2021 PBAC meeting

PBAC

7 May 2021 - The agenda for the July 2021 PBAC meeting has been updated. 

A summary of changes to the agenda is provided at the end of the agenda document.

The updated agenda includes 16 additions/revisions:

  • Five early re-entry resubmissions received
  • Seven scheduled for review under the process for reviewing positive recommendations not accepted by the applicant
  • Four minor revisions (not discussed further)

Early re-entry resubmissions - rejections from the March 2021 meeting

  • Darolutamide
  • Cedazuridine with decitabine
  • Melatonin
  • Riprentinib
  • Venetoclax

Review of PBAC recommendations

  • Budesonide - March 2019
  • Enoxaparin sodium - July 2020
  • Ramucirumab - March 2018
  • Secukinumab - March 2016
  • Sevelamer carbonate - November 2017
  • Tenofovir alafenamide fumarate - March 2017
  • Triglycerides - medium chain (Nutrini Peptisorb) - March 2019

We will discuss the issue of unresolved PBAC recommendations in a future issue of MAESTrO Daily. 

Read PBAC meeting agenda

Michael Wonder

Posted by:

Michael Wonder